Ecuador vs Zambia: Average cost of drugs for extensively drug-resistant tuberculosis
Ecuador
451 constant 2022 US$
in 2024
Zambia
600 constant 2022 US$
in 2024
Ecuador rank
50th
Zambia rank
49th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Ecuador
- Zambia
How they compare
Zambia currently reports 600 constant 2022 US$ against 451 constant 2022 US$ in Ecuador, a difference of 149 constant 2022 US$.
That makes Zambia's figure about 1.3 times Ecuador's.
Across all 5 years both countries report, Zambia has been ahead every year.
Ecuador ranks 50th and Zambia ranks 49th of 56 countries.
Zambia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Ecuador | Zambia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,241 constant 2022 US$ | 6,240 constant 2022 US$ | 4,999 constant 2022 US$ | Zambia |
| 2020s | 877.75 constant 2022 US$ | 3,210 constant 2022 US$ | 2,332 constant 2022 US$ | Zambia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Ecuador or Zambia?
- Zambia, at 600 constant 2022 US$ against 451 constant 2022 US$ in Ecuador as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Ecuador and Zambia?
- 149 constant 2022 US$, with Zambia ahead.
- How many years of comparable data are there for Ecuador and Zambia?
- 5 years are reported by both, from 2019 to 2024.
- How do Ecuador and Zambia rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Ecuador ranks 50th and Zambia ranks 49th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.